160 related articles for article (PubMed ID: 33552247)
21. Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes.
Wang J; Ai X; Qin T; Xu Z; Zhang Y; Liu J; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Cai W; Ru K; Jia Y; Huang G; Xiao Z
Oncotarget; 2017 Jan; 8(1):1603-1612. PubMed ID: 27906673
[TBL] [Abstract][Full Text] [Related]
22. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
23. Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution.
Jung SW; Lee SY; Jekarl DW; Kim M; Lim J; Kim Y; Han K; Kim YJ; Cho SG; Song J
Leuk Res; 2011 Jun; 35(6):735-40. PubMed ID: 21146871
[TBL] [Abstract][Full Text] [Related]
24. [Cytogenetic profile in patients with primary myelodysplastic syndrome].
Gritsaev SV; Martynkevich IS; Petrova EV; Martynenko LS; Ivanova MP; Aksenova VIu; Tsybakova NIu; Potikhonova NA; Abdulkadyrov KM
Ter Arkh; 2013; 85(7):43-9. PubMed ID: 24137946
[TBL] [Abstract][Full Text] [Related]
25. [The clinical features, cytogenetic characteristics and survival analysis of 550 myelodysplastic syndromes in a single center].
Zhang TT; Sun AN; Pan JL; Wu DP; Qiu HY; Tang XW; Miao M; Chen SN
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):864-869. PubMed ID: 27801317
[TBL] [Abstract][Full Text] [Related]
26. [Analysis on laboratory and clinical characteristics in 65 cases of myelodysplastic syndrome].
Chen BA; Gao C; Ding J; Ding JH; Sun YY; Zhao G; Cheng J; Wang J; Bao W; Song HH; Xia GH; Ma JL; Wu LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1472-6. PubMed ID: 20030929
[TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic Syndrome in Pakistan: Clinicohematological Characteristics, Cytogenetic Profile, and Risk Stratification.
Mahmood R; Altaf C; Ahmed P; Khan SA; Malik HS
Turk J Haematol; 2018 May; 35(2):109-115. PubMed ID: 28588002
[TBL] [Abstract][Full Text] [Related]
28. Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
Arenillas L; Calvo X; Luño E; Senent L; Alonso E; Ramos F; Ardanaz MT; Pedro C; Tormo M; Marco V; Montoro J; Díez-Campelo M; Brunet S; Arrizabalaga B; Xicoy B; Andreu R; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
J Clin Oncol; 2016 Sep; 34(27):3284-92. PubMed ID: 27382099
[TBL] [Abstract][Full Text] [Related]
29. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.
Zhao WL; Xu L; Wu W; Yan H; Tang W; Hu J; Chen Y; Li JM; Zeng XY; Xiong SM; Shen ZX; Chen Z; Wang ZY; Chen SJ
Hematol J; 2002; 3(3):137-44. PubMed ID: 12111649
[TBL] [Abstract][Full Text] [Related]
30. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
31. Cytogenetic characteristics in Vietnamese patients diagnosed with primary myelodysplastic syndromes.
Vu MP; Ha HQ; Nguyen CN
Leuk Res Rep; 2022; 18():100343. PubMed ID: 36032421
[TBL] [Abstract][Full Text] [Related]
32. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I
Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079
[TBL] [Abstract][Full Text] [Related]
33. [Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome].
Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Tiranova SA; Kakaĭ MP; Martynenko LS; Dziavgo LA
Ter Arkh; 2005; 77(7):22-7. PubMed ID: 16116904
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes.
Nomdedeu M; Calvo X; Pereira A; Carrió A; Solé F; Luño E; Cervera J; Vallespí T; Muñoz C; Gómez C; Arias A; Such E; Sanz G; Grau J; Insunza A; Calasanz MJ; Ardanaz MT; Hernández-Rivas JM; Azaceta G; Álvarez S; Sánchez J; Martín ML; Bargay J; Gómez V; Cervero CJ; Allegue MJ; Collado R; Campo E; Esteve J; Nomdedeu B; Costa D;
Genes Chromosomes Cancer; 2016 Apr; 55(4):322-7. PubMed ID: 26690722
[TBL] [Abstract][Full Text] [Related]
36. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
37. [Detection of chromosome abnormalities in myelodysplastic syndromes with interval fluorescence in situ hybridization].
Ru X; Li Q; Fang XS; Li Y; Wang X; Zhang LY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):116-20. PubMed ID: 23484703
[TBL] [Abstract][Full Text] [Related]
38. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
[TBL] [Abstract][Full Text] [Related]
39. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
[TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic Syndrome with Excess Blasts 2 (MDS-EB-2): A Historical Overview and Review of Forthcoming Classifications.
Tan JS; Gardner JA; Devitt KA; Conant JL
J Assoc Genet Technol; 2023; 49(1):24-30. PubMed ID: 36867850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
